Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sarepta Therapeutics (NQ: SRPT )

120.40 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 124
Open 120.40
Bid (Size) 118.17 (1)
Ask (Size) 122.00 (1)
Prev. Close 120.40
Today's Range 120.40 - 120.40
52wk Range 55.25 - 173.25
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics
Via Benzinga
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
These two could become direct competitors relatively soon. 
Via The Motley Fool

Performance

YTD
+25.14%
+25.14%
1 Month
-6.61%
-6.61%
3 Month
-20.51%
-20.51%
6 Month
-4.74%
-4.74%
1 Year
-2.45%
-2.45%

More News

Read More
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Via MarketBeat
Exposures Product Safety
Unveiling 26 Analyst Insights On Sarepta Therapeutics
Via Benzinga
How Is The Market Feeling About Sarepta Therapeutics?
Via Benzinga
A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Via Benzinga
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
From Sarepta Therapeutics, Inc.
Via Business Wire
These 2 Biotech Stocks Are Set to Soar
Via The Motley Fool
Smart Money Is Betting Big In SRPT Options
Via Benzinga
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
From Sarepta Therapeutics, Inc.
Via Business Wire
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Via Benzinga
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
Via Investor's Business Daily
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Via MarketBeat
2 Biotech Stocks to Buy Hand Over Fist in August
Via The Motley Fool
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Via Benzinga
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
Via Investor's Business Daily
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
Via InvestorPlace
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.